A prospective, randomized study of amikacin and gentamicin in seriousinfections with focus on efficacy, toxicity and duration of serum levels above the MIC

Publisher Website
Google Scholar
Abstract
A multicentre prospective randomized study of amikacin and gentamicin in 135 patients with serious infections is presented. Most patients were additionally given a penicillin derivative according to Swedish therapeutic traditions. Synergism was noted in the majority of the tested strains. Clinical cure was recorded in 80% and 76% respectively of the amikacin and gentamicin patient groups. Nephrotoxic reactions were statistically (PP<0.01). We suggest that the pharmacokinetic advantages of amikacin in comparison to gentamicin might be of practical importance in the prediction of serum levels thereby lowering the risk of toxic reactions.

This publication has 2 references indexed in Scilit: